- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02470364
Translation, Cross-cultural Adaptation and Validation of the MGQOL-15-F (MGQOL-15-F)
Study Overview
Status
Conditions
Detailed Description
It is a translation and validation of a quality of life scale.
Step 1: Translation and cultural adaptation (Forward and back translation, committee review, pre-testing with 10 patients for content and face validity).
Step 2 : Psychometric testing : Test-retest with a 2 day interval, correlation with clinical scores - the Myasthenic Muscle Score and the (MG-ADL) score and with a global quality of life score (WHOQOL-BREF).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75013
- Institute of Myology, La Pitié-Salpêtrière Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Auto-immune myasthenia gravis
- Age ≥ 18 years old
- Clinical Classification (MGFA) I-IV
- French speaking
Exclusion Criteria:
- cognitive or visual impairment which would limit the capacity to fill out the MGQOL-15-F
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Perceived quality of life measured via the MGQOL-15-F (French version of the MGQOL-15), a myasthenia-specific quality of life auto-questionnaire
Time Frame: 3 days
|
3 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Global quality of life evaluated via the WHOQOL-BREF scale
Time Frame: 1 day
|
1 day
|
|
Clinical evaluation : Myasthenic Muscle Score
Time Frame: 1 day
|
1 day
|
|
Disease severity assessed via the Myasthenic Muscle Score
Time Frame: 1 day
|
1 day
|
|
Impact of symptoms on daily activities and daily life using the MG-ADL score
Time Frame: 1day
|
1day
|
Collaborators and Investigators
Investigators
- Principal Investigator: Simone Birnbaum, Physiotherapist, Institute of Myology, La Pitié-Salpêtrière Hospital, 75013 Paris, France
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Immune System Diseases
- Neoplasms
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Neoplasms by Site
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Nervous System Neoplasms
- Paraneoplastic Syndromes, Nervous System
- Paraneoplastic Syndromes
- Neuromuscular Junction Diseases
- Myasthenia Gravis
Other Study ID Numbers
- MGQOL-15
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myasthenia Gravis
-
Myasthenia Gravis Foundation of AmericaAlira HealthRecruitingMyasthenia Gravis | Myasthenia Gravis, Generalized | Myasthenia Gravis Crisis | Myasthaenia Gravis | Myasthenia Gravis, Ocular | Myasthenia Gravis, Thymectomy | Myasthenia Gravis, Adult Form | Myasthenia Gravis Generalised | Myasthenia Gravis, MuSK | Myasthenia Gravis Exacerbations | Myasthenia | Myasthenia... and other conditionsUnited States
-
Assiut UniversityRecruitingNervous System Diseases | Autoimmune Diseases of the Nervous System | Thymoma | Myasthenia Gravis | Neuromuscular Junction Diseases | Myasthenia Gravis, Generalized | Myasthenia Gravis Crisis | Myasthenia Gravis, Ocular | Myasthenia Gravis, Juvenile Form | Thymus Hyperplasia | Myasthenia Gravis With Exacerbation... and other conditionsEgypt
-
argenxRecruitingGeneralized Myasthenia Gravis | Myasthenia Gravis | gMG | Generalized Myasthenia Gravis (gMG) | MG | AChR-Ab Seropositive Generalized Myasthenia GravisUnited States, Poland, Belgium, Spain, Italy
-
argenxRecruitingGeneralized Myasthenia Gravis | Myasthenia Gravis | gMG | Generalized Myasthenia Gravis (gMG) | MG | AChR-Ab Seropositive Generalized Myasthenia GravisUnited States, Spain, Belgium, Poland, Italy
-
University of Colorado, DenverargenxRecruitingMyasthenia Gravis Crisis | Myasthenia Gravis Exacerbations | AChR Myasthenia GravisUnited States
-
Shanghai Zhongshan HospitalHuashan Hospital; West China Hospital; Tang-Du Hospital; Second Affiliated Hospital... and other collaboratorsNot yet recruitingMyasthenia Gravis Associated With Thymoma | Efgartigimod | Intravenous ImmunoglobulinChina
-
argenxCompletedGeneralized Myasthenia Gravis | gMG | MG - Myasthenia GravisGeorgia, United States, Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Spain
-
argenxActive, not recruitingGeneralized Myasthenia Gravis | Myasthenia Gravis | Myasthenia Gravis, Generalized | gMGUnited States, Belgium, Denmark, Germany, China, Netherlands, Norway, Spain, Saudi Arabia, United Kingdom, Czechia, Serbia, Poland, Greece, Georgia, Romania, Finland, Hungary, France, Canada, Portugal, Cyprus
-
Universiti Putra MalaysiaEnrolling by invitationExperimental MyastheniaChina
-
Universiti Putra MalaysiaCompletedExperimental MyastheniaChina